Jane Street’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Jane Street’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-143,071	Closed	-$1.45M	–	10529
2022 Q4	$1.45M	Sell	143,071 -2,271	-2%	-$22.7K	﹤0.01%	4387
2022 Q3	$1.44M	Sell	145,342 -154,578	-52%	-$1.53M	﹤0.01%	4751
2022 Q2	$2.97M	Buy	299,920 +165,509	+123%	+$1.62M	﹤0.01%	3459
2022 Q1	$1.32M	Hold	134,411	–	–	﹤0.01%	5534
2021 Q4	$1.32M	Hold	134,411	–	–	﹤0.01%	5344
2021 Q3	$1.31M	Buy	134,411 +2,312	+2%	+$22.4K	﹤0.01%	5367
2021 Q2	$1.28M	Buy	132,099 +26,392	+25%	+$256K	﹤0.01%	5280
2021 Q1	$1.03M	Buy	+105,707	New	+$1.02M	﹤0.01%	5403

Jane Street's BIOT Position: Q1 2023 in Review

Jane Street sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 143,071 shares — an estimated $1.45M sold.

Jane Street first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $2.97M in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Jane Street reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Jane Street sold 143,071 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.45M.
Jane Street first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Jane Street's Biotech Acquisition Company Class A Ordinary Shares position peaked at $2.97M in Q2 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.